Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C-related mixed cryoglobulinemia

Blood

Volumn 116, Issue 3, 2010, Pages 326-334

  Saadoun, David ^a,b   Rigon, Mathieu Resche ^c   Sene, Damien ^a   Terrier, Benjamin ^a,b   Karras, Alexandre ^d   Perard, Laurent ^e   Schoindre, Yoland ^a   Coppéré, Brigitte ^e   Blanc, François ^f   Musset, Lucile ^a   Piette, Jean Charles ^a   Rosenzwajg, Michele ^b   Cacoub, Patrice ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

^f LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOGLOBULIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RITUXIMAB; VIRUS RNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PEGINTERFERON ALFA-2A; PEGINTERFERON ALFA-2B;

ADULT; ANEMIA; ARTICLE; B LYMPHOCYTE; BLOOD TOXICITY; CLINICAL TRIAL; CRYOGLOBULINEMIA; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; ERYSIPELAS; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEPATITIS C; HERPES ZOSTER; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REMISSION; SARCOIDOSIS; SERUM SICKNESS; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT RESPONSE; AGED; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COHORT STUDIES; CRYOGLOBULINEMIA; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77955857269     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-248518     Document Type: Article

References (38)

1. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980;69(2):287-308. (Pubitemid 10036826)
2. Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101-2108. (Pubitemid 44631398)
3. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia: a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40(6):837-856.
4. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490-1495.
5. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101(10):3818-3826. (Pubitemid 36857852)
6. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827-3834. (Pubitemid 36857853)
7. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2005;52(3):911-915. (Pubitemid 40365115)
8. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696-3706. (Pubitemid 44737183)
9. Mazzaro C, Franzin F, Tulissi P, et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer. 1996;77(12):2604-2613. (Pubitemid 126497594)
10. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004;19(12):3054-3061.
11. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford). 2006;45(7):;45:842- 846. (Pubitemid 43985372)
12. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: where do we stand? Ann Rheum Dis. 2008;67(3):283-287. (Pubitemid 351281259)
13. Cai FZ, Ahern M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol. 2006;33(6):1197-1198. (Pubitemid 43825478)
14. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation. 2005;80(11):1560-1564.
15. Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford). 2005;44(3):406. (Pubitemid 40361306)
16. Lamprecht P, Lerin-Lozano C, Merz H, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis. 2003;62(12):1230-1233. (Pubitemid 37500635)
17. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
18. Saadoun D, Resche-Rigon M, Sene D, Perard L, Piette JC, Cacoub P. Rituximab combined with Peg-Interferon-Ribavirin in refractory HCV-associated cryoglobulinemia vasculitis. Ann Rheum Dis. 2008;67(10):1431-1436.
19. Musset L, Diemert MC, Taibi F, et al. Characterization of cryoglobulins by immunoblotting. Clin Chem. 1992;38(6):798-802.
20. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57(5):775-788.
21. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
22. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20(1):15-20.
23. Potter KN, Li Y, Mageed RA, Jefferis R, Capra JD. Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8. Scand J Immunol. 1999;50(1):14-20. (Pubitemid 29298021)
24. Carbonari M, Caprini E, Tedesco T, et al. Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol. 2005;174(10):6532-6539. (Pubitemid 40667522)
25. Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-611. (Pubitemid 351294898)
26. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47(2):618-623.
27. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355-374. (Pubitemid 38887136)
28. Roccatello D, Isidoro C, Mazzucco G, et al. Role of monocytes in cryoglobulinemia-associated nephritis. Kidney Int. 1993;43(5):1150-1155.
29. Reininger L, Berney T, Shibata T, Spertini F, Merino R, Izui S. Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms. Proc Natl Acad Sci U S A. 1990;87(24):10038-10042. (Pubitemid 120016580)
30. Kikuchi S, Pastore Y, Fossati-Jimack L, et al. A transgenic mouse model of autoimmune glomerulonephritis and necrotizing arteritis associated with cryoglobulinemia. J Immunol. 2002;169(8):4644-4650. (Pubitemid 35178245)
31. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994;330(11):751-756. (Pubitemid 24080221)
32. Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84(10):3336-3343. (Pubitemid 24352895)
33. Zaja F, Vianelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma. 2003;44(11):1951-1955. (Pubitemid 37369630)
34. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood. 2008;111(11):5334-5341.
35. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood. 2008;111(3):1344-1356. (Pubitemid 351213421)
36. Levine JW, Gota C, Fessler BJ, Calabrese LH, Cooper SM. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol. 2005;32(6):1164-1167. (Pubitemid 40828106)
37. Saadoun D, Suarez F, Lefrere F, et al. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood. 2005;105(1):74-76. (Pubitemid 40053066)
38. Sene D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum. 2009;60(12):3848-3855.